(Q37691861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Optimising in vivo pharmacology studies--Practical PKPD considerations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

A Richard Green

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Piet H Van der Graaf

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

11 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

146-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20153442%20AND%20SRC:MED&resulttype=core&format=json

A novel type of implantable and programmable infusion pump for small laboratory animals

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Changes in plasma protein binding have little clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

On the influence of protein binding on pharmacological activity of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Correct assessment of new compounds using in vivo screening models can reduce false positives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Comparison of four basic models of indirect pharmacodynamic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Constant rate of infusion--improvement of tests for teratogenicity and embryotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

The Lilly Prize Lecture. 1996 keep on taking the tablets': pharmacological adaptation during long-term drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Neuropharmacology of 5-hydroxytryptamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Turnover modeling of non-esterified fatty acids in rats after multiple intravenous infusions of nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Mechanism-based pharmacodynamic modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

A dynamical systems analysis of the indirect response model with special emphasis on time to peak response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

A pharmacodynamic turnover model capturing asymmetric circadian baselines of body temperature, heart rate and blood pressure in rats: challenges in terms of tolerance and animal-handling effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Significance of protein binding in pharmacokinetics and pharmacodynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

The intellectual health of clinical drug evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Modeling blood/plasma concentrations in dosed feed and dosed drinking water toxicology studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002

Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.002